콘텐츠로 건너뛰기
Merck
모든 사진(1)

Key Documents

View All Documentation

890898C

Avanti

DOTMA

Avanti Research™ - A Croda Brand

동의어(들):

1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt)

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C42H84ClNO2
CAS Number:
104872-42-6
Molecular Weight:
670.57
UNSPSC 코드:
12352211
NACRES:
NA.25

형태

liquid

포장

pkg of 1 × 2.5 mL (890898C-25mg)
pkg of 2 × 4 mL (890898C-200mg)

제조업체/상표

Avanti Research™ - A Croda Brand

농도

10 mg/mL (890898C-25mg)
25 mg/mL (890898C-200mg)

응용 분야

advanced drug delivery

지질 유형

transfection
cationic lipids

배송 상태

dry ice

저장 온도

−20°C

SMILES string

[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]

애플리케이션

DOTMA is suitable for use in the synthesis of cationic microbubble.

생화학적/생리학적 작용

DOTMA is a cationic lipid used as a non-viral vector for gene therapy. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome - cell membrane interaction.

포장

5 mL Clear Glass Sealed Ampule (890898C-200mg)
5 mL Clear Glass Sealed Ampule (890898C-25mg)

법적 정보

Avanti Research is a trademark of Avanti Polar Lipids, LLC

또한 이 제품과 함께 일반적으로 구입

제품 번호
설명
가격

픽토그램

Skull and crossbonesHealth hazard
GHS06,GHS08

신호어

Danger

유해 및 위험 성명서

H302,H315,H319,H331,H336,H351,H361d,H372

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3

표적 기관

Liver,Kidney, Respiratory system

Storage Class Code

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

Flash Point (°F)

does not flash

Flash Point (°C)

does not flash

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
Jinhong Meng et al.
Scientific reports, 10(1), 1046-1046 (2020-01-25)
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein
Jayesh A Kulkarni et al.
ACS nano, 12(5), 4787-4795 (2018-04-04)
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration. However, the mechanism of formation and certain structural features of LNP-siRNA remain obscure.

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.